The effect of erythropoietin on creatine kinase MB levels during ischemia reperfusion injury in rats
Abstract
Objective: This experimental study examined the effect of erythropoietin (Epo) in rat model and particularly in an ischemia-reperfusion (IR) protocol. The effect of that molecule was studied biochemically using blood mean creatine kinase MB (CK-MB) levels.
Materials and methods: 40 rats of mean weight 247.7 g were used in the study. CK-MB levels were measured at 60 min (groups A and C) and at 120 min (groups B and D) of reperfusion. Erythropoietin was administered only in groups C and D.
Results: Erythropoietin administration kept non significantly increased the predicted CK-MB values by 4.28%+5.11% (P= 0.3721). Reperfusion time non significantly decreased the predicted CK-MB values by the same quantities 4.28%+5.11% (P= 0.3721). Interaction of erythropoietin administration and reperfusion time kept non significantly increased the predicted CK-MB values by 2.32%+3.09% (P= 0.4430).
Conclusions: Erythropoietin administration whether it interacted or not with reperfusion time kept short-term non significantly increased the predicted CK-MB values.
Downloads
References
Τsompos C, Panoulis C, Τοutouzas K, Triantafyllou A, Ζografos G, Papalois A. The effect of erythropoietin on calcium levels during hypoxia reoxygenation injury in rats. Geriatric care 2016;2:5722:12-16.
Τsompos C, Panoulis C, Τοutouzas K, Ζografos G, Papalois A. The effect of erythropoietin on albumins levels during hypoxia reoxygenation injury in rats. Research Journal of Pharmacology and Toxicology 2015;1(3):42-45.
Gonçalves ES, Rabelo CM, Prado Neto AX, et al: Effect of short-term ornithine alpha-ketoglutarate pretreatment on intestinal ischemia-reperfusion in rats. Acta Cir Bras. 2011;26 Suppl 1:2-7.
Jebeli M, Ghazinoor M, Mandegar MH, et al: Effect of milrinone on short-term outcome of patients with myocardial dysfunction undergoing coronary artery bypass graft: A randomized controlled trial. Cardiol J. 2010;17(1):73-8.
Sala MF, Bárcena JP, Rota JI, et al: Sustained ventricular tachycardia as a marker of inadequate myocardial perfusion during the acute phase of myocardial infarction. Clin Cardiol. 2002 Jul;25(7):328-34.
Serruys PW, de Feyter P, Macaya C, et al: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 Jun 26;287(24):3215-22.
Savchuk VI, Vinogradov AV, Pozin VM, et al: Activity of total serum creatine phosphokinase and its MB fraction in reversible coronary blood flow disorders in dogs in a chronic experiment. Kardiologiia. 1980 Jan;20(1):58-60.
Yang FL, Subeq YM, Chiu YH, et al: Recombinant human erythropoietin reduces rhabdomyolysis-induced acute renal failure in rats. Injury. 2012 Mar;43(3):367-73.
Popov AF, Schulz EG, Schmitto JD, et al: Relation between renal dysfunction requiring renal replacement therapy and promoter polymorphism of the erythropoietin gene in cardiac surgery. Artif Organs. 2010 Nov;34(11):961-8.
Wu WT, Hu TM, Lin NT, et al: Low-dose erythropoietin aggravates endotoxin-induced organ damage in conscious rats. Cytokine. 2010 Feb;49(2):155-62.
Cho SH, Lim HS, Ghim JL, et al: Pharmacokinetic, tolerability, and bioequivalence comparison of three different intravenous formulations of recombinant human erythropoietin in healthy Korean adult male volunteers: an open-label, randomized-sequence, three-treatment, three-way crossover study. Clin Ther. 2009 May;31(5):1046-53.
Groopman JE. Zidovudine intolerance. Rev Infect Dis. 1990 Jul-Aug;12 Suppl 5:S500-6.
Copyright (c) 2016 Research Journal of Pharmacology and Toxicology
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
A) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
B) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
C) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
D) Author agree to submit Copyright form after accepetance of article.
